Latest articles for News
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_593e026_110112_Pawlotsky_Jean_Michel.jpg)
ILC: Europe issues hepatitis C treatment priority list
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_0535233_hepC4.jpg)
ILC: HCV treatment delays dented efficacy in era before all-oral therapy
Key clinical point: Efficacy diminishes when HCV treatment is delayed, particularly in patients who progress to advanced cirrhosis. Major finding...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_068c15c_CDC_icon.jpg)
HCV spike in four Appalachian states tied to drug abuse
Key clinical point: Hepatitis C virus infections more than tripled among young people in Kentucky, Tennessee, Virginia, and West Virginia, and...
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_685c7a4_110121_Reddy_Rajender_PHILLY.jpg)
ILC: Real-world success for all-oral antiviral therapy in HCV-related cirrhosis
Key clinical point: An all-oral antiviral regimen appears effective and safe for most patients with decompensated cirrhosis due to chronic HCV...
Conference Coverage
Consider HCV ‘a cardiovascular risk factor’
Key clinical point: Chronic HCV infection was strongly linked to CV outcome and needs to be considered a CV risk factor. Major finding: Adjusted...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_d9a1188_Poordad_Fred_TX.jpg)
Interferon-free antiviral regimens achieve high response rates in HCV
Key clinical point: A 12-week course of oral daclatasvir, asunaprevir, and beclabuvir, with or without ribavirin achieves a high response rate in...
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_b0f4731_Mohanty_Arpan.jpg)
ILC: Statins linked to better outcomes in hepatitis C cirrhosis
Key clinical point: Hepatitis C–infected patients with associated cirrhosis had fewer deaths and decompensations when receiving statin treatment....
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_330ea7f_109839_Nyberg_Anders_SAN DIEGO.jpg)
HCV increases general cancer risk
Key clinical point: Chronic hepatitis C virus (HCV) infection raises the risk of all types of cancer, not just liver cancer. Major finding: The...
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_b104efd_hepatitis_c.jpg)
ILC: Unrecognized hepatitis C linked with advanced hepatic fibrosis
Key clinical point: One-fifth of Americans with unrecognized chronic hepatitis C infection likely have advanced hepatic fibrosis. Major finding:...
Conference Coverage
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_2117844_Zeuzem_Stefan.jpg)
ILC: New single daily pill eradicates hepatitis C
Key clinical point: Once-daily, single-pill combination treatment with grazoprevir and elbasvir for 12 weeks was safe and effective for...